Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
News-Medical.Net on MSN3d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...
News-Medical.Net on MSN5d
New trial shows oral semaglutide reduces cardiovascular events in diabetes patientsBoth the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even ...
MedPage Today on MSN6d
STRIDE: Semaglutide Shows It Has Legs in Peripheral Artery DiseaseCHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback